Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Argent Biopharma's Enterprise Value is $8.04 Mil.
Argent Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.61 Mil. Therefore, Argent Biopharma's EV-to-EBIT ratio for today is -1.43.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Argent Biopharma's Enterprise Value is $8.04 Mil.
Argent Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.40 Mil. Therefore, Argent Biopharma's EV-to-EBITDA ratio for today is -1.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Argent Biopharma's Enterprise Value is $8.04 Mil.
Argent Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.26 Mil. Therefore, Argent Biopharma's EV-to-Revenue ratio for today is 30.45.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Argent Biopharma (OTCPK:RGTLF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Argent Biopharma's current Enterprise Value is $8.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.61 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Argent Biopharma's current Enterprise Value is $8.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.40 Mil.
Argent Biopharma's current Enterprise Value is $8.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.26 Mil.
Argent Biopharma's current Enterprise Value is $8.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.99 Mil.
Argent Biopharma's current Enterprise Value is $8.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Argent Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma Enterprise Value Related Terms
Argent Biopharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Argent Biopharma's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a Enterprise Value of $8.04 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Argent Biopharma and its competitors.
Is Argent Biopharma's Enterprise Value too high?
Argent Biopharma's current Enterprise Value is $8.04 Mil.
How does Argent Biopharma's Enterprise Value compare to ZTS and UTHR?
Argent Biopharma's Enterprise Value of $8.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Enterprise Value is $8.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Enterprise Value is $8.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Enterprise Value is $8.04 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 